2,391
Views
4
CrossRef citations to date
0
Altmetric
Drug Profile

Teriflunomide for the treatment of relapsing–remitting multiple sclerosis

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Nukendra Prasad Nadella, Venkata Nadh Ratnakaram & N. Srinivasu. (2017) Quality-by-design-based development and validation of a stability-indicating UPLC method for quantification of teriflunomide in the presence of degradation products and its application to in-vitro dissolution. Journal of Liquid Chromatography & Related Technologies 40:10, pages 517-527.
Read now

Articles from other publishers (3)

M. Emin Çorman, Ahmet Cetinkaya, Canan Armutcu, Esen Bellur Atici, Lokman Uzun & Sibel A. Ozkan. (2022) A sensitive and selective electrochemical sensor based on molecularly imprinted polymer for the assay of teriflunomide. Talanta 249, pages 123689.
Crossref
Aaron E. Miller. (2016) Switching or Discontinuing Disease-Modifying Therapies for Multiple Sclerosis. CONTINUUM: Lifelong Learning in Neurology 22:3, pages 851-863.
Crossref
M. Emin Çorman, Ahmet Cetinkaya, Canan Armutcu, Esen Bellur Atici, Lokman Uzun & Sibel A. Ozkan. (2022) Sensitive and Selective Recognition of Teriflunomide Based on Molecularly Imprinted Electrochemical Sensor Via Newly Synthesized Functionalized Pyrrole Monomer: Pyrrole Histidine. SSRN Electronic Journal.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.